Search
forLearn
5 / 801 resultslearn Follicusan
learn SCUBE3
a signaling molecule from dermal papilla cells being actively researched
learn carrageenan
learn gentian
Research
5 / 20 results
research Histopathological Findings and Proliferative Activity of Canine Sebaceous Gland Tumours with a Predominant Reserve Cell Population
High proliferative activity and peripheral invasion indicate malignancy in canine sebaceous gland tumors; the term 'epithelioma' should be updated for clarity.
research Apocrine sweat gland obstruction by antiperspirants allowing transdermal absorption of cutaneous generated hormones and pheromones as a link to the observed incidence rates of breast and prostate cancer in the 20th century
The document suggests that blocking sweat glands with antiperspirants might allow skin-generated hormones to be absorbed, possibly increasing breast and prostate cancer risk.
research A 36-Year-Old Woman With an Unexpected Cause of Hypokalemia
A 36-year-old woman with low potassium levels was found to have Cushing disease, and after treatment, her potassium levels normalized.
research Proliferative and Non-Proliferative Lesions of the Rat and Mouse Integument
The project created a standardized system for classifying skin lesions in lab rats and mice.
research The Skin and Subcutaneous Tissues
The document concludes that skin and nail changes can indicate various underlying health conditions.
Community Join
5 / 1000+ resultscommunity SUBE3 for sale in the gray market?
SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.
community GT20029 - Promising phase II results
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community SCUBE3 and GT20029 could be the closet thing to a cure: Hair Follicle Regeneration and Protection Against DHT
SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.
community Anagenic is trying to compound Gt20029
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.